Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

home / authors / loyda-e.-braithwaite,-np,-university-of-wisconsin-carbone-cancer-center

Articles

Management of Adverse Effects in R/R HER2+ mBC

Management of Adverse Effects in R/R HER2+ mBC

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

HER2-targeted Therapy: Routes of Administration

HER2-targeted Therapy: Routes of Administration

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

Practical Management of Early Stage HER2+ Breast Cancer

Practical Management of Early Stage HER2+ Breast Cancer

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC